Sean Michael Smith - 02 Mar 2022 Form 3 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role: Principal Accounting Officer
Signature: /s/ Sean M. Smith
Issuer symbol: NGNE
Transactions as of: 02 Mar 2022
Net transactions value: $0
Form type: 3
Filing time: 03 Mar 2022, 15:38:16 UTC
Next filing: 04 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	NLTX	Common Stock						3,431	02 Mar 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NLTX	Employee Stock Option (Right to buy)							02 Mar 2022	Common Stock	26,000	$2.71	Direct	F1
holding	NLTX	Employee Stock Option (Right to buy)							02 Mar 2022	Common Stock	24,000	$6.80	Direct	F2
holding	NLTX	Employee Stock Option (Right to buy)							02 Mar 2022	Common Stock	15,000	$12.00	Direct	F3
holding	NLTX	Restricted Stock Units							02 Mar 2022	Common Stock	10,000		Direct	F4, F5, F6
holding	NLTX	Restricted Stock Units							02 Mar 2022	Common Stock	25,000		Direct	F5, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/4 of the shares subject to the option vested on October 21, 2020, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2	1/4 of the shares subject to the option will vest on August 3, 2022, and then 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3	1/4 of the shares subject to the option vested on August 10, 2021, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4	The restricted stock units ("RSUs") will vest as to 1/2 of the total number of shares underlying the award on each of August 10, 2022 and August 10, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F5	RSUs do not expire; they either vest or are canceled prior to the vesting date.
F6	Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F7	The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.